Hematological Cancers Market - Global Outlook and Forecast 2021-2027

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Hematological Cancers Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hematological Cancers Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hematological Cancers Overall Market Size
2.1 Global Hematological Cancers Market Size: 2021 VS 2027
2.2 Global Hematological Cancers Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hematological Cancers Players in Global Market
3.2 Top Global Hematological Cancers Companies Ranked by Revenue
3.3 Global Hematological Cancers Revenue by Companies
3.4 Top 3 and Top 5 Hematological Cancers Companies in Global Market, by Revenue in 2020
3.5 Global Companies Hematological Cancers Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Cancers Players in Global Market
3.6.1 List of Global Tier 1 Hematological Cancers Companies
3.6.2 List of Global Tier 2 and Tier 3 Hematological Cancers Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Hematological Cancers Market Size Markets, 2021 & 2027
4.1.2 Pharmacological Therapies
4.1.3 Stem Cell Transplantation
4.1.4 Surgery and Radiation Therapy
4.1.5 Anemia Treatment
4.1.6 Thrombosis Treatment
4.1.7 Neutopenia Treatment
4.1.8 Symptomatic treatment
4.2 By Type - Global Hematological Cancers Revenue & Forecasts
4.2.1 By Type - Global Hematological Cancers Revenue, 2016-2021
4.2.2 By Type - Global Hematological Cancers Revenue, 2022-2027
4.2.3 By Type - Global Hematological Cancers Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hematological Cancers Market Size, 2021 & 2027
5.1.2 Epidemiology
5.1.3 Pathophysiology of Leukemic Stem Cells
5.1.4 Kidney Diseases
5.1.5 Genetic Diseases
5.1.6 Other Diseases
5.2 By Application - Global Hematological Cancers Revenue & Forecasts
5.2.1 By Application - Global Hematological Cancers Revenue, 2016-2021
5.2.2 By Application - Global Hematological Cancers Revenue, 2022-2027
5.2.3 By Application - Global Hematological Cancers Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Hematological Cancers Market Size, 2021 & 2027
6.2 By Region - Global Hematological Cancers Revenue & Forecasts
6.2.1 By Region - Global Hematological Cancers Revenue, 2016-2021
6.2.2 By Region - Global Hematological Cancers Revenue, 2022-2027
6.2.3 By Region - Global Hematological Cancers Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Hematological Cancers Revenue, 2016-2027
6.3.2 US Hematological Cancers Market Size, 2016-2027
6.3.3 Canada Hematological Cancers Market Size, 2016-2027
6.3.4 Mexico Hematological Cancers Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Hematological Cancers Revenue, 2016-2027
6.4.2 Germany Hematological Cancers Market Size, 2016-2027
6.4.3 France Hematological Cancers Market Size, 2016-2027
6.4.4 U.K. Hematological Cancers Market Size, 2016-2027
6.4.5 Italy Hematological Cancers Market Size, 2016-2027
6.4.6 Russia Hematological Cancers Market Size, 2016-2027
6.4.7 Nordic Countries Hematological Cancers Market Size, 2016-2027
6.4.8 Benelux Hematological Cancers Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Hematological Cancers Revenue, 2016-2027
6.5.2 China Hematological Cancers Market Size, 2016-2027
6.5.3 Japan Hematological Cancers Market Size, 2016-2027
6.5.4 South Korea Hematological Cancers Market Size, 2016-2027
6.5.5 Southeast Asia Hematological Cancers Market Size, 2016-2027
6.5.6 India Hematological Cancers Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Hematological Cancers Revenue, 2016-2027
6.6.2 Brazil Hematological Cancers Market Size, 2016-2027
6.6.3 Argentina Hematological Cancers Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hematological Cancers Revenue, 2016-2027
6.7.2 Turkey Hematological Cancers Market Size, 2016-2027
6.7.3 Israel Hematological Cancers Market Size, 2016-2027
6.7.4 Saudi Arabia Hematological Cancers Market Size, 2016-2027
6.7.5 UAE Hematological Cancers Market Size, 2016-2027
7 Players Profiles
7.1 Karyopharm Therapeutics
7.1.1 Karyopharm Therapeutics Corporate Summary
7.1.2 Karyopharm Therapeutics Business Overview
7.1.3 Karyopharm Therapeutics Hematological Cancers Major Product Offerings
7.1.4 Karyopharm Therapeutics Hematological Cancers Revenue in Global (2016-2021)
7.1.5 Karyopharm Therapeutics Key News
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporate Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Hematological Cancers Major Product Offerings
7.2.4 Johnson & Johnson Hematological Cancers Revenue in Global (2016-2021)
7.2.5 Johnson & Johnson Key News
7.3 Roche Diagnostics A/S
7.3.1 Roche Diagnostics A/S Corporate Summary
7.3.2 Roche Diagnostics A/S Business Overview
7.3.3 Roche Diagnostics A/S Hematological Cancers Major Product Offerings
7.3.4 Roche Diagnostics A/S Hematological Cancers Revenue in Global (2016-2021)
7.3.5 Roche Diagnostics A/S Key News
7.4 AbbVie
7.4.1 AbbVie Corporate Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Hematological Cancers Major Product Offerings
7.4.4 AbbVie Hematological Cancers Revenue in Global (2016-2021)
7.4.5 AbbVie Key News
7.5 Novartis
7.5.1 Novartis Corporate Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Hematological Cancers Major Product Offerings
7.5.4 Novartis Hematological Cancers Revenue in Global (2016-2021)
7.5.5 Novartis Key News
7.6 Kite Pharma
7.6.1 Kite Pharma Corporate Summary
7.6.2 Kite Pharma Business Overview
7.6.3 Kite Pharma Hematological Cancers Major Product Offerings
7.6.4 Kite Pharma Hematological Cancers Revenue in Global (2016-2021)
7.6.5 Kite Pharma Key News
7.7 Celgene Corporation
7.7.1 Celgene Corporation Corporate Summary
7.7.2 Celgene Corporation Business Overview
7.7.3 Celgene Corporation Hematological Cancers Major Product Offerings
7.4.4 Celgene Corporation Hematological Cancers Revenue in Global (2016-2021)
7.7.5 Celgene Corporation Key News
7.8 Abbott Laboratories
7.8.1 Abbott Laboratories Corporate Summary
7.8.2 Abbott Laboratories Business Overview
7.8.3 Abbott Laboratories Hematological Cancers Major Product Offerings
7.8.4 Abbott Laboratories Hematological Cancers Revenue in Global (2016-2021)
7.8.5 Abbott Laboratories Key News
7.9 Beckman Coulter
7.9.1 Beckman Coulter Corporate Summary
7.9.2 Beckman Coulter Business Overview
7.9.3 Beckman Coulter Hematological Cancers Major Product Offerings
7.9.4 Beckman Coulter Hematological Cancers Revenue in Global (2016-2021)
7.9.5 Beckman Coulter Key News
7.10 HemoCue AB
7.10.1 HemoCue AB Corporate Summary
7.10.2 HemoCue AB Business Overview
7.10.3 HemoCue AB Hematological Cancers Major Product Offerings
7.10.4 HemoCue AB Hematological Cancers Revenue in Global (2016-2021)
7.10.5 HemoCue AB Key News
7.11 C. R. Bard
7.11.1 C. R. Bard Corporate Summary
7.11.2 C. R. Bard Business Overview
7.11.3 C. R. Bard Hematological Cancers Major Product Offerings
7.11.4 C. R. Bard Hematological Cancers Revenue in Global (2016-2021)
7.11.5 C. R. Bard Key News
7.12 Siemens AG
7.12.1 Siemens AG Corporate Summary
7.12.2 Siemens AG Business Overview
7.12.3 Siemens AG Hematological Cancers Major Product Offerings
7.12.4 Siemens AG Hematological Cancers Revenue in Global (2016-2021)
7.12.5 Siemens AG Key News
7.13 Sysmex
7.13.1 Sysmex Corporate Summary
7.13.2 Sysmex Business Overview
7.13.3 Sysmex Hematological Cancers Major Product Offerings
7.13.4 Sysmex Hematological Cancers Revenue in Global (2016-2021)
7.13.5 Sysmex Key News
7.14 Mindray Medical International Limited
7.14.1 Mindray Medical International Limited Corporate Summary
7.14.2 Mindray Medical International Limited Business Overview
7.14.3 Mindray Medical International Limited Hematological Cancers Major Product Offerings
7.14.4 Mindray Medical International Limited Hematological Cancers Revenue in Global (2016-2021)
7.14.5 Mindray Medical International Limited Key News
7.15 Bio-Rad Laboratories
7.15.1 Bio-Rad Laboratories Corporate Summary
7.15.2 Bio-Rad Laboratories Business Overview
7.15.3 Bio-Rad Laboratories Hematological Cancers Major Product Offerings
7.15.4 Bio-Rad Laboratories Hematological Cancers Revenue in Global (2016-2021)
7.15.5 Bio-Rad Laboratories Key News
7.16 The Medicine Company
7.16.1 The Medicine Company Corporate Summary
7.16.2 The Medicine Company Business Overview
7.16.3 The Medicine Company Hematological Cancers Major Product Offerings
7.16.4 The Medicine Company Hematological Cancers Revenue in Global (2016-2021)
7.16.5 The Medicine Company Key News
7.17 Pharmacyclics
7.17.1 Pharmacyclics Corporate Summary
7.17.2 Pharmacyclics Business Overview
7.17.3 Pharmacyclics Hematological Cancers Major Product Offerings
7.17.4 Pharmacyclics Hematological Cancers Revenue in Global (2016-2021)
7.17.5 Pharmacyclics Key News
7.18 Horiba
7.18.1 Horiba Corporate Summary
7.18.2 Horiba Business Overview
7.18.3 Horiba Hematological Cancers Major Product Offerings
7.18.4 Horiba Hematological Cancers Revenue in Global (2016-2021)
7.18.5 Horiba Key News
7.19 DiagnoCure Inc.
7.19.1 DiagnoCure Inc. Corporate Summary
7.19.2 DiagnoCure Inc. Business Overview
7.19.3 DiagnoCure Inc. Hematological Cancers Major Product Offerings
7.19.4 DiagnoCure Inc. Hematological Cancers Revenue in Global (2016-2021)
7.19.5 DiagnoCure Inc. Key News
7.20 Astellas Pharma US
7.20.1 Astellas Pharma US Corporate Summary
7.20.2 Astellas Pharma US Business Overview
7.20.3 Astellas Pharma US Hematological Cancers Major Product Offerings
7.20.4 Astellas Pharma US Hematological Cancers Revenue in Global (2016-2021)
7.20.5 Astellas Pharma US Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer


List of Tables
Table 1. Hematological Cancers Market Opportunities & Trends in Global Market
Table 2. Hematological Cancers Market Drivers in Global Market
Table 3. Hematological Cancers Market Restraints in Global Market
Table 4. Key Players of Hematological Cancers in Global Market
Table 5. Top Hematological Cancers Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Hematological Cancers Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Hematological Cancers Revenue Share by Companies, 2016-2021
Table 8. Global Companies Hematological Cancers Product Type
Table 9. List of Global Tier 1 Hematological Cancers Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Cancers Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type

Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US